Lipids and lipoprotein fractions after cyclopenthiazide and oxprenolol: a double-blind crossover study.

Crisp, A. J., Kennedy, P. G. E., Hoffbrand, B. I.,, Ebbutt, A. F. and Carruthers, M. (1980) Lipids and lipoprotein fractions after cyclopenthiazide and oxprenolol: a double-blind crossover study. Current Medical Research and Opinion, 7(2), pp. 101-103. (doi:10.1185/03007998009112034)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1185/03007998009112034

Abstract

A double-blind crossover study was carried out to investigate the effects of cyclopenthiazide and oxprenolol on blood lipids in 20 previously untreated patients with mild to moderate hypertension. After a 4-week placebo period, patients received at random either 8-weeks' treatment with the two drugs followed by 8 weeks on cyclopenthiazide alone, or the reversed sequence. Daily doses were 160 mg slow-release oxprenolol and/or 0.25 mg cyclopenthiazide during the first 4 weeks of each treatment period, after which the dosage was doubled. Data from 13 patients who completed the trial showed no significant changes in the blood levels of triglycerides, total cholesterol or LDL and HDL cholesterol fractions. These findings are discussed in relation to published studies on the effects of other beta-blockers on blood lipids.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Kennedy, Professor Peter
Authors: Crisp, A. J., Kennedy, P. G. E., Hoffbrand, B. I.,, Ebbutt, A. F., and Carruthers, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Current Medical Research and Opinion
Publisher:Informa Healthcare
ISSN:0300-7995
ISSN (Online):1473-4877

University Staff: Request a correction | Enlighten Editors: Update this record